[Frontiers in Bioscience S3, 1-15, January 1, 2011]

Management of type-2 diabetes with anti-platelet therapies: special reference to aspirin

Gundu H. R. Rao

Laboratory Medicine and Pathology, Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota 55455

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Platelet Physiology
4. Arachidonic Acid Metabolism
5. Platelet Hyperfunction
6. Vascular Dysfunction
7. Clinical Use of Aspirin
8. Aspirin Resistance
9. Prevalence of Aspirin Resistance
10. Management of Diabetes with Anti-platelet Therapy
11. Limitations of Current 3.2.
12. Strategies and Future Directions 13. Conclusions
14. Acknowledgements
15. References

1. ABSTRACT

Adult onset diabetes currently affects 380 million individuals worldwide and is expected to affect 380 million by 2025. Major defects contributing to this complex disease are insulin resistance and beta cell dysfunction. More than 80% of patients professing to type-2 diabetes are insulin resistant. Recent studies have shown that the Indian subcontinent ranks very high in the occurrence of Diabetes and Coronary artery disease (1, 2, 3). Patients with Type 2 diabetes carry an equivalent cardiovascular risk to that of a non-diabetic individual who has already experienced a coronary event. The risk of coronary artery disease in any given population seems to be 2-3 times higher in diabetics than non-diabetics. Inflammation, platelet activation, endothelial dysfunction and coagulation are the four processes, whose interplay determines the development of cardiovascular disease. In this article, we provide a brief overview on platelet physiology, vascular dysfunction, platelet hyper-function, and the role of platelet related clinical complications in diabetes mellitus and what is know about the management of this complex disease with anti-platelet drugs such as aspirin and Clopidogrel.